Eleftha 150mg Injection

1. Product Introduction

Eleftha 150mg Injection is an advanced monoclonal antibody formulation that contains Trastuzumab (150mg), a highly targeted therapy used in the treatment of certain types of HER2-positive cancers, especially breast cancer and gastric (stomach) cancer. Trastuzumab is a recombinant DNA-derived humanized monoclonal antibody that selectively binds to the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells.

HER2-positive cancers are aggressive and tend to grow and spread faster than HER2-negative cancers. Trastuzumab works by attaching itself to the HER2 receptors on the surface of cancer cells, inhibiting their growth and triggering the body’s immune system to destroy them. Eleftha 150mg is administered intravenously under the supervision of a trained oncologist.

This injection has transformed cancer treatment by significantly improving survival rates and quality of life in HER2-positive patients when used either alone or in combination with chemotherapy.

2. Uses of This Medicine

Eleftha 150mg Injection is primarily used in the treatment of:

• HER2-Positive Breast Cancer:

  • Early-stage breast cancer (as adjuvant therapy after surgery and chemotherapy)

  • Metastatic breast cancer (advanced stage or when cancer has spread to other parts of the body)

• HER2-Positive Gastric Cancer:

  • For patients with metastatic adenocarcinoma of the stomach or gastroesophageal junction that overexpress the HER2 protein.

The usage depends on several factors including cancer stage, patient health status, and other ongoing treatments. It may be used as monotherapy or in combination with other anti-cancer medications like paclitaxel, cisplatin, or capecitabine.

3. Benefits of This Medicine

Eleftha 150mg Injection provides a range of clinical and therapeutic benefits:

• Targeted Cancer Therapy: Directly targets HER2-positive cancer cells, sparing normal cells and reducing overall toxicity.

• Improved Survival Rate: Significantly increases disease-free survival and overall survival in HER2-positive breast and gastric cancer patients.

• Delayed Disease Progression: Helps slow down the progression of the disease and reduces the risk of cancer recurrence.

• Enhanced Effectiveness of Chemotherapy: When used in combination, Trastuzumab enhances the effect of traditional chemotherapy drugs.

• Well-Tolerated: Though potent, it is generally well-tolerated when monitored and administered properly.

• Improves Quality of Life: By managing symptoms and controlling disease progression, it contributes to a better quality of life for cancer patients.

4. Side Effects

While Eleftha 150mg Injection is highly effective, it can cause some side effects. Patients receiving this medicine are usually monitored closely to manage any adverse effects.

Common Side Effects:

• Fever or chills

• Headache

• Nausea and vomiting

• Diarrhea

• Cough and upper respiratory tract infections

• Fatigue or weakness

• Body aches or joint pain

• Rash or skin reactions

Serious Side Effects (require immediate medical attention):

• Heart problems (congestive heart failure, reduced heart function)

• Shortness of breath or chest pain

• Severe allergic reactions (swelling, difficulty breathing, itching)

• Low white blood cell count (increased risk of infections)

• Liver enzyme elevations

Patients should undergo cardiac function tests (like echocardiograms) before starting therapy and at regular intervals during treatment.

5. Frequently Asked Questions (FAQ)

Q1. What is Eleftha 150mg Injection used for?
It is used to treat HER2-positive breast and gastric cancers. It helps in slowing or stopping the growth of cancer cells and can be used as monotherapy or in combination with chemotherapy.

Q2. How is Eleftha administered?
Eleftha 150mg is given as an intravenous infusion by a healthcare professional in a hospital or cancer treatment center. The first dose is usually given more slowly to monitor for any allergic reaction.

Q3. How often do I need to take this injection?
The frequency depends on your treatment plan. Typically, it’s administered every week or every three weeks, depending on the dose and your doctor’s recommendation.

Q4. Can Eleftha be used during pregnancy?
No, Trastuzumab should not be used during pregnancy as it can cause serious harm to the unborn baby. Women of childbearing age should use effective contraception during treatment and for at least 7 months after the last dose.

Q5. What tests are needed before starting this medicine?
Patients must be tested for HER2 protein overexpression using biopsy samples. Cardiac function tests are also essential before starting and during the treatment.